J&J's favorite CAR-T developer, currently owned by a Chinese CRO, is laying the groundwork for US IPO
GenScript, the low-profile owner of CAR-T dark horse Nanjing Legend Biotech, is hatching a plan to spin out its famous subsidiary and shoot for a US IPO.
The contract research organization disclosed its proposal in a filing to the Hong Kong Stock Exchange, where it’s been listed since late 2015. With the HKEX’s blessing, Legend Biotech has submitted a draft registration statement to the SEC, it wrote.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.